RNWL
INTERNATIONAL REGISTRATION RENEWED
10/06/2023
Back to search
Official data from USPTO
FKB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
FKB
ST13
US500000079141948Class
5, 10, 35, 40, 42, 44
Filing
79141948
Registration
4779408
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
11/05/2023
Trademark type
Word
Nice classes
5, 10, 35, 40, 42, 44
Filing date
11/15/2013
Registration date
07/28/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/11/2022
Last transaction
11/05/2023
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
tokyo 100-8185, JP
Examiner
CRAWFORD, MARY
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd .
FUJIFILM KYOWA KIRIN BIOLOGICS; Co., Ltd.
Representatives
Kaushal Odedra ODEDRA LAW OFFICE, PLLC
Technical classification
Nice Classes
Class 5Class 10Class 35Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases; Pharmaceutical preparations for use in connection with humans for the treatment of parasitic diseases; Pharmaceutical preparations for use in connection with humans for the prevention of parasitic diseases; Pharmaceutical preparations for use in connection with humans for the treatment of neoplasms; Pharmaceutical preparations for use in connection with humans for the prevention of neoplasms; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the blood; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the blood; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of blood-forming organs; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of blood-forming organs; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of certain disorders involving the immune mechanism; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of certain disorders involving the immune mechanism; Pharmaceutical preparations for use in connection with humans for the treatment of endocrine diseases; Pharmaceutical preparations for use in connection with humans for the prevention of endocrine diseases; Pharmaceutical preparations for use in connection with humans for the treatment of nutritional diseases; Pharmaceutical preparations for use in connection with humans for the prevention of nutritional diseases; Pharmaceutical preparations for use in connection with humans for the treatment of metabolic diseases; Pharmaceutical preparations for use in connection with humans for the prevention of metabolic diseases; Pharmaceutical preparations for use in connection with humans for the treatment of mental disorders; Pharmaceutical preparations for use in connection with humans for the prevention of mental disorders ; Pharmaceutical preparations for use in connection with humans for the treatment of behavioural disorders; Pharmaceutical preparations for use in connection with humans for the prevention of behavioural disorders; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the nervous system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the nervous system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the eye; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the eye; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of eye adnexa; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of eye adnexa; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the ear; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the ear; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the mastoid process; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the mastoid process; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the circulatory system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the circulatory system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the respiratory system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the respiratory system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the digestive system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the digestive system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the skin; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the skin; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of subcutaneous tissue; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of subcutaneous tissue; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the musculoskeletal system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the musculoskeletal system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the connective tissue; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the connective tissue; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the genitourinary system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the genitourinary system; Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases and diabetes occurred in pregnancy; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases and diabetes occurred in pregnancy; Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases occurred in childbirth; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases occurred in childbirth; Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases occurred in the puerperium; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases occurred in the puerperium; Pharmaceutical preparations for use in connection with humans for the treatment of nutritional deficiency conditions originating in the perinatal period; Pharmaceutical preparations for use in connection with humans for the prevention of nutritional deficiency conditions originating in the perinatal period; Pharmaceutical preparations for use in connection with humans for the treatment of congenital malformations; Pharmaceutical preparations for use in connection with humans for the prevention of congenital malformations; Pharmaceutical preparations for use in connection with humans for the treatment of deformations; Pharmaceutical preparations for use in connection with humans for the prevention of deformations; Pharmaceutical preparations for use in connection with humans for the treatment of chromosomal abnormalities; Pharmaceutical preparations for use in connection with humans for the prevention of chromosomal abnormalities; Prescribed pharmaceutical preparations for the treatment of infectious diseases; Prescribed pharmaceutical preparations for the prevention of infectious diseases; Prescribed pharmaceutical preparations for the treatment of parasitic diseases; Prescribed pharmaceutical preparations for the prevention of parasitic diseases; Prescribed pharmaceutical preparations for the treatment of neoplasms; Prescribed pharmaceutical preparations for the prevention of neoplasms; Prescribed pharmaceutical preparations for the treatment of diseases of the blood; Prescribed pharmaceutical preparations for the prevention of diseases of the blood Prescribed pharmaceutical preparations for the treatment of diseases of blood-forming organs; Prescribed pharmaceutical preparations for the prevention of diseases of blood-forming organs; Prescribed pharmaceutical preparations for the treatment of diseases of certain disorders involving the immune mechanism; Prescribed pharmaceutical preparations for the prevention of diseases of certain disorders involving the immune mechanism; Prescribed pharmaceutical preparations for the treatment of endocrine diseases; Prescribed pharmaceutical preparations for the prevention of endocrine diseases; Prescribed pharmaceutical preparations for the treatment of nutritional diseases; Prescribed pharmaceutical preparations for the prevention of nutritional diseases; Prescribed pharmaceutical preparations for the treatment of metabolic diseases; Prescribed pharmaceutical preparations for the prevention of metabolic diseases; Prescribed pharmaceutical preparations for the treatment of mental disorders; Prescribed pharmaceutical preparations for the prevention of mental disorders; Prescribed pharmaceutical preparations for the treatment of behavioural disorders; Prescribed pharmaceutical preparations for the prevention of behavioural disorders; Prescribed pharmaceutical preparations for the treatment of diseases of the nervous system; Prescribed pharmaceutical preparations for the prevention of diseases of the nervous system; Prescribed pharmaceutical preparations for the treatment of diseases of the eye; Prescribed pharmaceutical preparations for the prevention of diseases of the eye; Prescribed pharmaceutical preparations for the treatment of diseases of eye adnexa; Prescribed pharmaceutical preparations for the prevention of diseases of eye adnexa; Prescribed pharmaceutical preparations for the treatment of diseases of the ear; Prescribed pharmaceutical preparations for the prevention of diseases of the ear; Prescribed pharmaceutical preparations for the treatment of diseases of the mastoid process; Prescribed pharmaceutical preparations for the prevention of diseases of the mastoid process; Prescribed pharmaceutical preparations for the treatment of diseases of the circulatory system; Prescribed pharmaceutical preparations for the prevention of diseases of the circulatory system; Prescribed pharmaceutical preparations for the treatment of diseases of the respiratory system; Prescribed pharmaceutical preparations for the prevention of diseases of the respiratory system; Prescribed pharmaceutical preparations for the treatment of diseases of the digestive system; Prescribed pharmaceutical preparations for the prevention of diseases of the digestive system; Prescribed pharmaceutical preparations for the treatment of diseases of the skin; Prescribed pharmaceutical preparations for the prevention of diseases of the skin; Prescribed pharmaceutical preparations for the treatment of diseases of subcutaneous tissue; Prescribed pharmaceutical preparations for the prevention of diseases of subcutaneous tissue; Prescribed pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; Prescribed pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; Prescribed pharmaceutical preparations for the treatment of diseases of the connective tissue; Prescribed pharmaceutical preparations for the prevention of diseases of the connective tissue; Prescribed pharmaceutical preparations for the treatment of diseases of the genitourinary system; Prescribed pharmaceutical preparations for the prevention of diseases of the genitourinary system; Prescribed pharmaceutical preparations for the treatment of infectious diseases and diabetes occurred in pregnancy; Prescribed pharmaceutical preparations for the prevention of infectious diseases and diabetes occurred in pregnancy; Prescribed pharmaceutical preparations for the treatment of infectious diseases occurred in childbirth; Prescribed pharmaceutical preparations for the prevention of infectious diseases occurred in childbirth; Prescribed pharmaceutical preparations for the treatment of infectious diseases occurred in the puerperium; Prescribed pharmaceutical preparations for the prevention of infectious diseases occurred in the puerperium; Prescribed pharmaceutical preparations for the treatment of nutritional deficiency conditions originating in the perinatal period; Prescribed pharmaceutical preparations for the prevention of nutritional deficiency conditions originating in the perinatal period; Prescribed pharmaceutical preparations for the treatment of congenital malformations; Prescribed pharmaceutical preparations for the prevention of congenital malformations; Prescribed pharmaceutical preparations for the treatment of deformations; Prescribed pharmaceutical preparations for the prevention of deformations; Prescribed pharmaceutical preparations for the treatment of chromosomal abnormalities; Prescribed pharmaceutical preparations for the prevention of chromosomal abnormalities; Biological pharmaceutical preparations for the treatment of infectious diseases; Biological pharmaceutical preparations for the prevention of infectious diseases; Biological pharmaceutical preparations for the treatment of parasitic diseases; Biological pharmaceutical preparations for the prevention of parasitic diseases; Biological pharmaceutical preparations for the treatment of neoplasms; Biological pharmaceutical preparations for the prevention of neoplasms; Biological pharmaceutical preparations for the treatment of diseases of the blood; Biological pharmaceutical preparations for the prevention of diseases of the blood; Biological pharmaceutical preparations for the treatment of diseases of blood-forming organs; Biological pharmaceutical preparations for the prevention of diseases of blood-forming organs; Biological pharmaceutical preparations for the treatment of diseases of certain disorders involving the immune mechanism; Biological pharmaceutical preparations for the prevention of diseases of certain disorders involving the immune mechanism; Biological pharmaceutical preparations for the treatment of endocrine diseases; Biological pharmaceutical preparations for the prevention of endocrine diseases; Biological pharmaceutical preparations for the treatment of nutritional diseases; Biological pharmaceutical preparations for the prevention of nutritional diseases; Biological pharmaceutical preparations for the treatment of metabolic diseases; Biological pharmaceutical preparations for the prevention of metabolic diseases; Biological pharmaceutical preparations for the treatment of mental disorders; Biological pharmaceutical preparations for the prevention of mental disorders; Biological pharmaceutical preparations for the treatment of behavioural disorders; Biological pharmaceutical preparations for the prevention of behavioural disorders; Biological pharmaceutical preparations for the treatment of diseases of the nervous system; Biological pharmaceutical preparations for the prevention of diseases of the nervous system; Biological pharmaceutical preparations for the treatment of diseases of the eye; Biological pharmaceutical preparations for the prevention of diseases of the eye; Biological pharmaceutical preparations for the treatment of diseases of eye adnexa; Biological pharmaceutical preparations for the prevention of diseases of eye adnexa; Biological pharmaceutical preparations for the treatment of diseases of the ear; Biological pharmaceutical preparations for the prevention of diseases of the ear; Biological pharmaceutical preparations for the treatment of diseases of the mastoid process; Biological pharmaceutical preparations for the prevention of diseases of the mastoid process; Biological pharmaceutical preparations for the treatment of diseases of the circulatory system; Biological pharmaceutical preparations for the prevention of diseases of the circulatory system; Biological pharmaceutical preparations for the treatment of diseases of the respiratory system; Biological pharmaceutical preparations for the prevention of diseases of the respiratory system; Biological pharmaceutical preparations for the treatment of diseases of the digestive system; Biological pharmaceutical preparations for the prevention of diseases of the digestive system; Biological pharmaceutical preparations for the treatment of diseases of the skin; Biological pharmaceutical preparations for the prevention of diseases of the skin; Biological pharmaceutical preparations for the treatment of diseases of subcutaneous tissue; Biological pharmaceutical preparations for the prevention of diseases of subcutaneous tissue; Biological pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; Biological pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; Biological pharmaceutical preparations for the treatment of diseases of the connective tissue; Biological pharmaceutical preparations for the prevention of diseases of the connective tissue; Biological pharmaceutical preparations for the treatment of diseases of the genitourinary system; Biological pharmaceutical preparations for the prevention of diseases of the genitourinary system; Biological pharmaceutical preparations for the treatment of infectious diseases and diabetes occurred in pregnancy; Biological pharmaceutical preparations for the prevention of infectious diseases and diabetes occurred in pregnancy; Biological pharmaceutical preparations for the treatment of infectious diseases occurred in childbirth; Biological pharmaceutical preparations for the prevention of infectious diseases occurred in childbirth; Biological pharmaceutical preparations for the treatment of infectious diseases occurred in the puerperium; Biological pharmaceutical preparations for the prevention of infectious diseases occurred in the puerperium; Biological pharmaceutical preparations for the treatment of nutritional deficiency conditions originating in the perinatal period; Biological pharmaceutical preparations for the prevention of nutritional deficiency conditions originating in the perinatal period; Biological pharmaceutical preparations for the treatment of congenital malformations; Biological pharmaceutical preparations for the prevention of congenital malformations; Biological pharmaceutical preparations for the treatment of deformations; Biological pharmaceutical preparations for the prevention of deformations; Biological pharmaceutical preparations for the treatment of chromosomal abnormalities; Biological pharmaceutical preparations for the prevention of chromosomal abnormalities;bandages for dressings
Class 10
Apparatus for drug administrationdrug delivery systemsinjectorautoinjector; Therapeutic inhalerssold empty; High frequency electromagnetic therapy apparatus; Oxygen inhalaters for therapeutic purposes; Ultraviolet radiator units for therapeutic purposes; Defibrillators; Pneumothorax apparatusmedical apparatus for diagnosing or treating respiratory conditions; Heart pacemakers; Mercury arc lamp units for therapeutic purposes; Infrared radiator units for therapeutic purposes; Puncture apparatus for therapeutic purposesmedical devices for closing wounds; Lavage apparatus for therapeutic purposesapparatus for washing out body cavities; Carbon arc lamp units for therapeutic purposes; Injection syringessyringe barrels; Injection needles; Infusion apparatus for therapeutic purposesinfusion pumps for delivering measured amounts of solutions into the bloodstream over time; Ultrasonic therapy machines and apparatus; Short wave therapy machines and apparatus; Therapeutic bath apparatus and instrumentsappliances for washing body cavities; Massage apparatus for medical purposes; Low frequency electric therapy apparatus; Static electric therapy apparatus; Dialyzersblood component separation apparatus for medical purposes; Acupuncture needles; Sprayers for medical purposesdrug delivery sprayers sold empty; Suture apparatus for medical purposessuture needles and suture materials; Radioisotope therapy apparatus and instruments; Incubators for babies; Blood transfusion apparatus; Containers and trays specially designed for transporting and holding pharmaceuticals; Injection device for pharmaceuticals; Injection instruments without needles; Injection instruments with needles
Class 35
Providing information concerning commercial sales in the field of pharmaceuticals
Class 40
Custom manufacture of pharmaceuticals
Class 42
Pharmaceutical research; pharmaceutical development
Class 44
Pharmaceutical information services provided via the Internetproviding information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; medical information services provided via the Internet; providing medical information
Publications
History of USPTO decisions and trademark events.
51 publications found
FINP
FINAL DECISION TRANSACTION PROCESSED BY IB
06/06/2023
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
04/14/2023
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
04/14/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
04/14/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/15/2023
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
10/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
05/30/2022
RFNT
REFUSAL PROCESSED BY IB
03/21/2022
C71T
CANCELLED SECTION 71
02/11/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/31/2016
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
12/15/2015
XXCR
GENERIC MADRID TRANSACTION CREATED
12/15/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/28/2015
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
10/20/2015
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
10/09/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
07/28/2015
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/17/2015
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/01/2015
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/01/2015
PUBO
PUBLISHED FOR OPPOSITION
05/12/2015
GPNX
NOTIFICATION PROCESSED BY IB
05/08/2015
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/22/2015
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/22/2015
NPUB
NOTICE OF PUBLICATION
04/22/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/07/2015
ALIE
ASSIGNED TO LIE
04/07/2015
CNEA
EXAMINERS AMENDMENT MAILED
03/20/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/19/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
03/19/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/19/2015
CNFR
FINAL REFUSAL MAILED
02/06/2015
CNFR
FINAL REFUSAL WRITTEN
02/05/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/16/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/15/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/15/2015
CNRT
NON-FINAL ACTION MAILED
07/22/2014
CNRT
NON-FINAL ACTION WRITTEN
07/21/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/30/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/30/2014
ALIE
ASSIGNED TO LIE
06/19/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/11/2014
RFNP
REFUSAL PROCESSED BY IB
04/25/2014
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/25/2014
RFRR
REFUSAL PROCESSED BY MPU
03/25/2014
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/25/2014
CNRT
NON-FINAL ACTION WRITTEN
03/24/2014
DOCK
ASSIGNED TO EXAMINER
03/24/2014
MAFR
APPLICATION FILING RECEIPT MAILED
02/04/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/31/2014
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/30/2014
Continuous trademark protection
Get notified about every new filing that threatens FKB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.